Like a number of other people, I have a lot of questions about the impact of the new guidelines on the life sciences ecosystem. Quebec has adopted the Quebec 2017-2027 life sciences strategy, which is in fact an economic development tool. The same concern comes up in the brief submitted by the LifeSciences British Columbia organization.
Regarding the reform you are proposing, people are not seeing a concrete analysis of the direct impacts it would have on the life sciences ecosystem. I am talking about impacts not only on industry, but also on research institutes, teaching hospitals, research organizations under contract and clinical trial sites.
Could you assure us today that you have taken into account the overall impact of the new guidelines? I assume that, in five years, you have had enough time to produce those analyses. If so, how have you integrated this into your thought process and your reform?